These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19900844)

  • 1. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
    Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
    de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
    de Andrés C; Aristimuño C; Bartolomé M; de Las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2009 Jul; 212(1-2):112-20. PubMed ID: 19446889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased CD8+ central memory T cells in patients with multiple sclerosis.
    Liu GZ; Fang LB; Hjelmström P; Gao XG
    Mult Scler; 2007 Mar; 13(2):149-55. PubMed ID: 17439879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Frisullo G; Nociti V; Iorio R; Plantone D; Patanella AK; Tonali PA; Batocchi AP
    Hum Immunol; 2010 May; 71(5):437-41. PubMed ID: 20138197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Numerical defects in CD8+CD28- T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis.
    Mikulkova Z; Praksova P; Stourac P; Bednarik J; Strajtova L; Pacasova R; Belobradkova J; Dite P; Michalek J
    Cell Immunol; 2010; 262(2):75-9. PubMed ID: 20219185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a.
    Dressel A; Mirowska-Guzel D; Gerlach C; Weber F
    Acta Neurol Scand; 2007 Sep; 116(3):164-8. PubMed ID: 17714329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls.
    Haegele KF; Stueckle CA; Malin JP; Sindern E
    J Neuroimmunol; 2007 Feb; 183(1-2):168-74. PubMed ID: 17084910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of regulatory CD8+ T-lymphocytes and fall of activated CD8+ T-lymphocytes after i.v. methyl-prednisolone for multiple sclerosis relapse.
    Aristimuño C; Navarro J; de Andrés C; Martínez-Ginés L; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2008 Nov; 204(1-2):131-5. PubMed ID: 18835045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
    Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M
    Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memory and naïve B-cell subsets in patients with multiple sclerosis.
    Niino M; Hirotani M; Miyazaki Y; Sasaki H
    Neurosci Lett; 2009 Oct; 464(1):74-8. PubMed ID: 19666086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment.
    Frisullo G; Iorio R; Plantone D; Marti A; Nociti V; Patanella AK; Batocchi AP
    Mult Scler; 2011 May; 17(5):556-66. PubMed ID: 21177324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy.
    Chiarini M; Serana F; Zanotti C; Capra R; Rasia S; Rottoli M; Rovaris M; Caputo D; Cavaletti G; Frigo M; Frigeni B; Clerici R; Rezzonico M; Caimi L; Imberti L
    Mult Scler; 2012 Jun; 18(6):788-98. PubMed ID: 22086901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
    Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
    J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis.
    Krakauer M; Sorensen PS; Sellebjerg F
    J Neuroimmunol; 2006 Dec; 181(1-2):157-64. PubMed ID: 17081623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.